oti-calm 10 mg/40 mg/g picături auriculare, soluţie
flumed-farm srl - lidocainum + phenazonum - picături auriculare, soluţie - 10 mg/40 mg/g
bronchipret tp
bionorica se - germania - plante (ciubotica cucului+cimbru) - compr. film. - expectorante excl. combinatii cu antitusive
herbion sirop de ciuboţica cucului 3,08 g/5 ml
krka d.d., novo mesto - extras primulae rădăcină + extract de ierburi thymi - sirop - 3,08 g/5 ml
herbion sirop de ciuboţica cucului 3,08 g/5 ml
krka d.d., novo mesto - extras primulae rădăcină + extract de ierburi thymi - sirop - 3,08 g/5 ml
blincyto
amgen europe b.v. - blinatumomab - leucemia limfoblastică limfoblastică a celulelor precursoare - agenți antineoplazici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
besponsa
pfizer europe ma eeig - inotuzumab ozogamicin - leucemia limfoblastică limfoblastică a celulelor precursoare - agenți antineoplazici - besponsa este indicat în monoterapie pentru tratamentul pacienților adulți cu recidivat sau refractar cd22-pozitiv cu celule b precursoare leucemie limfoblastică acută (all). pacienți adulți cu cromozom philadelphia pozitiv (ph+) recidivat sau refractar cu celule b precursoare toate ar fi eșuat tratamentul cu cel puțin 1 inhibitor de tirozin kinaza (tki).
atriance
sandoz pharmaceuticals d.d. - nelarabine - precursor t-cell leucemia limfoblastică-limfom - agenți antineoplazici - nelarabina este indicat pentru tratamentul pacienților cu celule t leucemie limfoblastică acută (t) și t-celule de limfom limfoblastic (t-lbl) a căror boală nu a răspuns sau care a recidivat după tratamentul cu cel puțin două regimuri chimioterapice. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - alți agenți antineoplazici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
vacuum tubes recoltoare vidate edta k2, 2 ml, cod eticheta standard: c34vt1013, cod eticheta dubla: c34vt1013dl
sc tody laboratories int. srl -
vacuum tubes recoltoare vidate edta k2, 3 ml, cod eticheta standard: c34vt1014, cod eticheta dubla: c34vt1014dl
sc tody laboratories int. srl -